Pemfigoid
Sist oppdatert: Sist revidert:
Sist revidert av:Terje Johannessen
Definisjon:
Bulløs pemfigoid er en autoimmun og relativt benign sykdom med spente subepidermale bullae på erytematøs eller normalt utseende hud
Forekomst:
Insidens er funnet å være 4,3 per 100.000 personår. Rammer særlig eldre personer
Symptomer:
Debuterer gjerne med sterkt kløende, urtikarialiknende eksantem og etter hvert danning av store, spente blemmer
Funn:
Kliniske funn er opptil flere cm store halvkuleformede spente blærer som er utbredt over huden. Ca 1/3 har slimhinnelesjoner
Diagnostikk:
Aktuelle tilleggsundersøkelser er autoantistoffer, ev. histologi
Behandling:
Vanligvis systemiske steroider, noen ganger immundempende midler, ev. tetrasyklin, ev. lokale steroider
- Petronic-Rosic V. Bullous pemphigoid. BestPractice, last updated 11 Dec, 2020.
- Chan LS. Bullous penphigoid. Medscape, last updated Jul, 2017.
- Walsh SR, Hogg D, Mydlarski PR. Bullous pemphigoid: From bench to bedside. Drugs 2005;65:905-926. PubMed
- Langan SM, Smeeth L, Hubbard R. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180. PubMed
- Lamb PM, Abell E, Tharp M, et al. Prodromal bullous pemphigoid. Int J Dermatol 2006;45:209-214. PubMed
- Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev 2014; 13:477. PubMed
- Tran JT, Mutasim DF. Localized bullous pemphigoid: a commonly delayed diagnosis. Int J Dermatol 2005; 44:942. PubMed
- Maity S, Banerjee I, Sinha R et al. Nikolsky's sign: A pathognomic boon. J Family Med Prim Care. 2020 Feb 28;9(2):526-530. PMID: 32318376 PubMed
- Leiferman KM. Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid. UpToDate, last updated May 22, 2017. www.uptodate.com
- Holsen SD, Johannessen AC. Sykdommer som affiserer hud og munnslimhinne. Tidsskr Nor Lægeforen 2006; 126: 1214-7. Tidsskrift for Den norske legeforening
- Chalmers JR, Wojnarowska F, Kirtschig G, et al. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. Health Technol Assess. 2017; 21:1-90. PMID: 28406394 PubMed
- James T, Salman S, Stevenson B, et al. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid. Clin Immunol 2019; 198: 54-6. pmid:30557620 PubMed
- Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389: 1630-8. pmid:28279484 PubMed
- Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: A retrospective review of mayo clinic experience. Mayo Clin Proc 2005;80:41-47. PubMed
- Schmidt E, Bröcker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008 Feb;34(1):56-64. PubMed
- Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol 1999;41:266-268. PubMed
- Baum S, Sakka N, Artsi O, et al. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev 2014; 13:482. PubMed
- Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008 May;144(5):612-6. PMID: 18490587 PubMed
- Terje Johannessen, professor i allmennmedisin, Trondheim
- Morten Dalaker, avtalespesialist i hudsykdommer, Trondheim Hudlegesenter, Carl Johans gt 3, 7010 Trondheim